Keywords
chronic heart failure
stimulating growth factor expressed by gene 2
variability of the sST2 level
How to Cite
Abstract
The article presents the results of studying the variability of the level of soluble growth stimulating factor expressed by gene 2 (sST2) in plasma in patients with hypertension depending on various clinical characteristics. An open observational one-point randomized comparative study included 118 patients with stage II hypertension. The main group included 89 patients with stage II hypertension and various clinical forms of atrial fibrillation. The comparison group included 29 patients with stage II hypertension without atrial fibrillation. All patients underwent a general clinical examination. In addition, plasma levels of sST2 were determined. In accordance with the aim and objectives of the study, plasma levels of sST2 were analyzed depending on the clinical characteristics of the patients, the main risk factors and the nature of the damage to the target organs. The calculation of different levels of the biomarker was carried out, followed by the selection of groups with a relatively low, intermediate and relatively high level of sST2. In the course of the study, it was determined that in patients with atrial fibrillation, a significantly higher level of sST2 is observed in paroxysmal and permanent compared to persistent form of arrhythmia. A significant correlation (p<0.01) between the content of sST2 in plasma and the severity of the clinical course of arrhythmia, determined by the EHRA (European Heart Rhythm Association) class, has been proven. In addition, in patients with stage II hypertension with/without atrial fibrillation, increased plasma levels of sST2 are associated with the presence of concomitant chronic coronary disease, the functional class of chronic heart failure according to the NYHA (New York Heart Association) and the presence of such factors risk as pulse arterial pressure >60 mm Hg and type II diabetes.
Keywords: chronic coronary disease; chronic heart failure; stimulating growth factor expressed by gene 2; variability of the sST2 level.
References
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, Wainford RD, Williams B, Schutte AE. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334-57. DOI: 10.1161/HYPERTENSIONAHA.120.15026. PMID: 32370572.
Atrial fibrillation: diagnosis and management. London: National Institute for Health and Care Excellence (NICE); 2021 Apr 27. (NICE Guideline, No.196.) Available at: https://www.ncbi.nlm.nih.gov/books/NBK571337/
Ivanov V, Shushkovska Y, Afanasiuk O, Pentiuk L. The consequence of biomarkers of myocardial fibrosis in the prediction of arrhythmias in patients with hypertension in combination with coronary heart disease (literature review). Med. perspekt. [Internet]. 2020;25(4):22-31. Available at: http://journals.uran.ua/index.php/2307-0404/article/view/221225
Cao Z, Jia Y, Zhu B. BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine. Int J Mol Sci. 2019;20(8):1820. DOI: 10.3390/ijms20081820. PMID: 31013779.
Bahuleyan CG, Alummoottil GK, Abdullakutty J, Lordson AJ, Babu S, Krishnakumar VV, et al. Prognostic value of soluble ST2 biomarker in heart failure patients with reduced ejection fraction – A multicenter study. Indian Heart J. 2018;70(Suppl 1):S79-84. DOI: 10.1016/j.ihj.2017.09.010. PMID: 30122243.
Wang Z, Pan X, Xu H, Wu Y, Jia X, Fang Y, et al. Serum Soluble ST2 Is a Valuable Prognostic Biomarker in Patients With Acute Heart Failure. Front Cardiovasc Med. 2022;9:812654. DOI: 10.3389/fcvm.2022.812654. PMID: 35224046.
Januzzi JL, Horne BD, Moore SA, Galenko O, Snow GL, Brunisholz KD, et al. Interleukin receptor family member ST2 concentrations in patients following heart transplantation. Biomarkers. 2013;18(3):250-6. DOI: 10.3109/1354750X.2013.773081. PMID: 23557127.
Weinberg EO. ST2 protein in heart disease: from discovery to mechanisms and prognostic value. Biomark Med. 2009;3(5):495-511. DOI: 10.2217/bmm.09.56. PMID: 20477519.
McCormack T, Boffa RJ, Jones NR, Carville S, McManus RJ. The 2018 ESC/ESH hypertension guideline and the 2019 NICE hypertension guideline, how and why they differ. Eur Heart J. 2019;40(42):3456-8. DOI: 10.1093/eurheartj/ehz681. PMID: 31589745.
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. DOI: 10.1093/eurheartj/ehaa612. Erratum in: Eur Heart J. 2021;42(5):507. Erratum in: Eur Heart J. 2021;42(5):546-7. Erratum in: Eur Heart J. 2021;42(40):4194. PMID: 32860505.
Goette A, Auricchio A, Boriani G, Braunschweig F, Terradellas JB, Burri H, et al. EHRA White Paper: knowledge gaps in arrhythmia management-status 2019. Europace. 2019;21(7):993-4. DOI: 10.1093/europace/euz055. PMID: 30882143.
Manito N. New 2021 ESC/HFA heart failure guidelines. A practical comprehensive approach. Rev Esp Cardiol (Engl Ed). 2022;75(7):548-51. DOI: 10.1016/j.rec.2022.02.006. PMID: 35337780. [In English, Spanish].
Ciccone MM, Cortese F, Gesualdo M, Riccardi R, Di Nunzio D, Moncelli M, et al. A novel cardiac bio-marker: ST2: a review. Molecules. 2013;18(12):15314-28. DOI: 10.3390/molecules181215314. PMID: 24335613.
Kokkoz C, Bilge A, Irik M, Dayangac HI, Hayran M, Akarca FK, et al. Prognostic value of plasma ST2 in patients with non-ST segment elevation acute coronary syndrome. Turk J Emerg Med. 2018;18(2):62-6. DOI: 10.1016/j.tjem.2018.01.003. PMID: 29922732.
Maslovskyi VI, Mezhiievska IA. The level of growth stimulating factor expressed by gene 2 and troponin I in the blood plasma of NSTEMI patients depending on different clinical characteristics. Wiad Lek. 2022;75(1 pt 2):289-92. PMID: 35182137.
Kong L, Hu P, Li C, Jiang T, Hu G. The Correlation between sST2 and Atrial Fibrillation and Its Clinical Significance. Yangtze Medicine. 2020;4:277-83. DOI: 10.4236/ym.2020.44025.
Fousteris E, Melidonis A, Panoutsopoulos G, Tzirogiannis K, Foussas S, Theodosis-Georgilas A, et al. Toll/interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction. Cardiovasc Diabetol. 2011;10:101. DOI: 10.1186/1475-2840-10-101. PMID: 22104207.
Caporali A, Meloni M, Miller AM, Vierlinger K, Cardinali A, Spinetti G, et al. Soluble ST2 is regulated by p75 neurotrophin receptor and predicts mortality in diabetic patients with critical limb ischemia. Arterioscler Thromb Vasc Biol. 2012;32(12):e149-60. DOI: 10.1161/ATVBAHA.112.300497. PMID: 23065828.
Tonacci A, Quattrocchi P, Gangemi S. IL33/ST2 Axis in Diabetic Kidney Disease: A Literature Review. Medicina (Kaunas). 2019;55(2):50. DOI: 10.3390/medicina55020050. PMID: 30769901.
Zong X, Fan Q, Zhang H, Yang Q, Xie H, Chen Q, et al. Soluble ST2 levels for predicting the presence and severity of metabolic syndrome. Endocr Connect. 2021;10(3):336-44. DOI: 10.1530/EC-20-0645. PMID: 33617466.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.